Hostname: page-component-7b7567c8c-2jgqx Total loading time: 0 Render date: 2026-11-19T20:35:26.586Z Has data issue: false hasContentIssue false

Clinical Signs with Modified Electroconvulsive Therapy

Published online by Cambridge University Press:  29 January 2018

J. G. Whitwam
Affiliation:
Department of Anaesthetics, General Infirmary at Leeds
T. Moreton
Affiliation:
Department of Psychiatry, University of Leeds
J. Norman
Affiliation:
Department of Anaesthetics, The General Infirmary at Leeds
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

In many electroconvulsive therapy centres atropine is used to mitigate adverse effects resulting from stimulation of the parasympathetic nervous system, while the violence of muscular contractions is controlled with a muscle relaxant. It is customary to secure hypnosis with a short acting barbiturate prior to administration of the relaxant. The first report of the use of thiopentone for E.C.T. was by Rubinstein (1945), and methohexitone (Lilly 25398) was introduced by Friedman (1959). The use of succinylcholine (iodide) for E.C.T. was first reported by Holmberg and Thesleff (1951). The neurological signs during unmodified E.C.T. have been well documented (e.g. Klein and Early, 1948a, 1948b, 1949; Kalinowsky and Hoch, 1952). There is as yet no comparable detailed clinical description of E.C.T. when modified by atropine and a short acting muscle relaxant preceded by a barbiturate. This discussion is limited to some of those signs which may be of assistance in the management of therapy.

Information

Type
Research Article
Copyright
Copyright © Royal College of Psychiatrists, 1963

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.